Ranbaxy Laboratories Ltd (RANB.NS)

RANB.NS on National Stock Exchange of India

706.60INR
23 Jan 2015
Change (% chg)

Rs9.50 (+1.36%)
Prev Close
Rs697.10
Open
Rs705.00
Day's High
Rs714.65
Day's Low
Rs700.00
Volume
715,917
Avg. Vol
1,187,091
52-wk High
Rs714.65
52-wk Low
Rs305.20

RANB.NS

Chart for RANB.NS

About

Ranbaxy Laboratories Limited (Ranbaxy) is a research-based international pharmaceutical company serving customers in over 150 countries. The Company develops, manufactures and markets generic, branded generic, value-added and over-the-counter (OTC) products, anti-retrovirals (ARVs), active pharmaceutical ingredients (APIs) and... (more)

Overall

Beta: 0.53
Market Cap(Mil.): Rs300,773.81
Shares Outstanding(Mil.): 425.66
Dividend: --
Yield (%): --

Financials

  RANB.NS Industry Sector
P/E (TTM): 524.96 40.21 40.82
EPS (TTM): 1.35 -- --
ROI: -- 19.07 18.35
ROE: -- 19.85 19.25
Search Stocks

Nifty falls to one-month low, tracking weak China

MUMBAI - The Nifty fell for a third consecutive day on Tuesday, closing at a one-month low, as investors cashed out positions tracking a selloff in Chinese markets, hurting blue-chips such as Oil and Natural Gas Corp.

09 Dec 2014

CORRECTED-Indian shares fall to one-month low, tracking weak China

(Corrects to say shares fell for a third consecutive day, not second, in paragraph 1)

09 Dec 2014

Sun Pharma, Ranbaxy gain after regulator approves deal

Reuters Market Eye - Sun Pharmaceutical Industries gains 1.4 percent, Ranbaxy Laboratories up 2.8 percent

09 Dec 2014

CCI clears Sun Pharma-Ranbaxy deal

MUMBAI - The Competition Commission of India (CCI) approved generic drugmaker Sun Pharmaceutical Industries' $3.2 billion bid to buy Ranbaxy Laboratories, but ordered the firms to divest seven products to ensure the deal doesn't harm competition.

09 Dec 2014

MARKET EYE -India' Sun Pharma, Ranbaxy gain after regulator approves deal

** Sun Pharmaceutical Industries gains 2.9 pct, Ranbaxy Laboratories up 3.7 pct ** India's antitrust regulator approved Sun Pharma's $3.2 bln bid to buy Ranbaxy ** Approval to speed up the merger process - Traders ** Only key approval pending now is of US Federal Trade Commission, which will come in due course of time - Analysts (Reuters Messaging: abhishek.vishnoi.thomsonreuters.com@reuters.net)

09 Dec 2014

Antitrust regulator CCI clears Sun Pharma-Ranbaxy deal

MUMBAI - The Competition Commission of India (CCI) approved generic drugmaker Sun Pharmaceutical Industries' $3.2 billion bid to buy Ranbaxy Laboratories , but ordered the firms to divest seven products to ensure the deal doesn't harm competition.

08 Dec 2014

India's regulator clears Sun Pharma-Ranbaxy deal

MUMBAI - India's antitrust regulator approved generic drugmaker Sun Pharmaceutical Industries' $3.2 billion bid to buy Ranbaxy Laboratories, but ordered the firms to divest seven products to ensure the deal doesn't harm competition.

08 Dec 2014

UPDATE 1-India's regulator clears Sun Pharma-Ranbaxy deal

(Adds details from CCI order, comments from Sun and Ranbaxy, background)

08 Dec 2014

India's antitrust regulator clears Sun Pharma-Ranbaxy deal

MUMBAI, Dec 8 - India's antitrust regulator said on Monday it has approved generic drugmaker Sun Pharmaceutical Industries Ltd's $3.2 billion bid to buy smaller rival Ranbaxy Laboratories Ltd, subject to the companies divesting seven products.

08 Dec 2014

AstraZeneca, Ranbaxy prevail in Nexium antitrust trial

REUTERS - A Massachusetts jury has found that an agreement between AstraZeneca Plc and Ranbaxy Laboratories Ltd to delay the launch of a generic version of AstraZeneca's heartburn drug Nexium was not anticompetitive.

06 Dec 2014

Earnings vs. Estimates

Search Stocks